New pill tested for tough skin conditions
NCT ID NCT06982352
Summary
This is an early-stage study to check the safety and how the body processes a new oral drug called LPX-TI641. It will involve about 48 adults with moderate-to-severe eczema (atopic dermatitis) or plaque psoriasis. Participants will take the drug or a placebo pill daily for 28 days so researchers can monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Investigations of Texas
RECRUITINGDallas, Texas, 75075, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Red River Research Partners
RECRUITINGFargo, North Dakota, 58103, United States
-
Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITINGAmman, Jordan, B204, Jordan
Conditions
Explore the condition pages connected to this study.